Medindia

Health Canada Grants Authorization for Leqembi® (lecanemab)

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment ...

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease

In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment ...
Medindia

Could Resetting the Brain’s Internal Clock Slow Alzheimer’s?

Alzheimer’s disease is notorious for scrambling patients’ daily rhythms. Restless nights with little sleep and increased ...

First Alzheimer's pill for genetically at high risk shows promise in phase 3 trial

Phase 3 clinical trial results of an investigational drug has shown benefits in treating people with APOE4/4 with early ...